Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience

Overview of attention for article published in Cancer Management and Research, September 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma

Article in Expert Review of Anticancer Therapy (March 2023)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective

Article in Frontiers in Oncology (March 2023)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers

Article in Ecancermedicalscience (January 2023)